Kytogenics Pharmaceuticals, Inc. is a biomedical company engaged in the development of products based on its medical device and drug delivery proprietary platform technologies.

The Phase III Clinical Trial for the reduction of gynecological post-surgical adhesions, its most advanced medical device product, has been initiated. Kytogenics' oral delivery of peptides is its most exciting opportunity in the drug delivery area. Strategic alliances have been entered into with major healthcare companies.